Henry Schein Given New $127.00 Price Target at Leerink Swann (HSIC)
Leerink Swann lifted their target price on shares of Henry Schein (NASDAQ:HSIC) from $120.00 to $127.00 in a research note issued on Tuesday. The firm currently has a “market perform” rating on the stock. Leerink Swann’s target price indicates a potential upside of 10.14% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at ISI Group cut their price target on shares of Henry Schein from $130.00 to $127.00 in a research note on Monday. They now have a “neutral” rating on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Henry Schein in a research note on Wednesday, June 11th. They now have a $126.00 price target on the stock. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $118.17.
Shares of Henry Schein (NASDAQ:HSIC) traded down 1.24% on Tuesday, hitting $115.31. 627,133 shares of the company’s stock traded hands. Henry Schein has a 1-year low of $100.64 and a 1-year high of $120.99. The stock’s 50-day moving average is $118.7 and its 200-day moving average is $117.0. The company has a market cap of $9.843 billion and a price-to-earnings ratio of 22.97.
Henry Schein (NASDAQ:HSIC) last released its earnings data on Monday, August 4th. The company reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.33 by $0.02. The company had revenue of $2.60 billion for the quarter, compared to the consensus estimate of $2.56 billion. During the same quarter in the previous year, the company posted $1.23 earnings per share. The company’s revenue for the quarter was up 9.3% on a year-over-year basis. Analysts expect that Henry Schein will post $5.38 EPS for the current fiscal year.
Henry Schein, Inc is a provider of health care products and services to office-based practitioners. It conducts its business through two segments: healthcare distribution and technology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.